{"entity":{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","aka":["Zenith Epigenetics Ltd."],"tldr":"Zenith Epigenetics is a Calgary biotech whose oral BET inhibitor ZEN-3694 is being tested with enzalutamide in castration-resistant prostate cancer and with PARP inhibitors and immunotherapy in other tumours.","summary":"Zenith Epigenetics, spun out of Resverlogix, develops ZEN-3694 (ZEN003694), an oral inhibitor of bromodomain and extra-terminal (BET) proteins that reduces transcription of MYC and androgen receptor-driven programmes. ZEN-3694 has been studied with enzalutamide in metastatic castration-resistant prostate cancer, including a randomised phase 2b trial, with talazoparib in triple-negative breast cancer, and with pembrolizumab, and is in a National Cancer Institute-sponsored trial in NUT carcinoma.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.zenithepigenetics.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["zen-3694"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Calgary","country":"CA","companyType":"biotech","website":"https://www.zenithepigenetics.com/","investors":[],"funding":[]},"route":"/companies/zenith-epigenetics/","neighbours":{"drug":[{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/"}]}}